Introduction Etodolac was a popular nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and inflammation. In the United States, it was available in both prescription and over-the-counter forms and was widely prescribed by doctors. Unfortunately, in 2020, the Food and Drug Administration (FDA) announced the recall of Etodolac due to concerns over its safety. In this article, we will explore why this popular pain medication was discontinued and what this means for doctors and patients alike.
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that was used to treat mild to moderate pain and inflammation. It was available both as a prescription medication and as an over-the-counter medication. It was widely prescribed by doctors for a variety of conditions including arthritis, menstrual cramps, and other musculoskeletal conditions.
The FDA announced the recall of Etodolac in 2020 due to safety concerns. The FDA noted that the drug had been associated with an increased risk of serious cardiovascular events, including heart attack and stroke. Additionally, the FDA noted that the drug had been associated with an increased risk of gastrointestinal bleeding. As a result, the FDA determined that the risks associated with Etodolac outweighed the benefits and recommended that it be discontinued.
For doctors, the discontinuation of Etodolac means that they can no longer prescribe it to their patients. However, doctors can still prescribe other NSAIDs to treat pain and inflammation. Additionally, doctors should be aware of the potential risks associated with other NSAIDs and should only prescribe them when the benefits outweigh the risks. For patients, the discontinuation of Etodolac means that they may need to find an alternative medication to treat their pain and inflammation. Patients should speak to their doctor about other options that may be available to them. Additionally, patients should be aware of the potential risks associated with other NSAIDs and should only take them if the benefits outweigh the risks.
Etodolac was a popular nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and inflammation. Unfortunately, in 2020, the FDA announced the recall of Etodolac due to safety concerns. This means that doctors can no longer prescribe it to their patients and patients may need to find an alternative medication to treat their pain and inflammation. Doctors and patients should be aware of the potential risks associated with other NSAIDs and should only take them if the benefits outweigh the risks.
1.
More Positive Survival Data in Lung Cancer With Perioperative Therapy
2.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
3.
Study finds 10% of pediatric blood cancers may stem from medical imaging radiation
4.
For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.
5.
Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.
1.
Case Study: Artificial Intelligence in Early Cancer Detection
2.
Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment
3.
What is Mullerian and How Does it Affect Your Health
4.
AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies
5.
Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Should We Use DARA Up Front As First-Line Therapy in MM?
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation